fda都已经批了，日_老虎社区_美港股上老虎 - 老虎社区

fda都已经批了，日本，和加拿大市场都打开了看好

异动解读 | Kalvista Pharmaceuticals股价盘中大跌5.53%，2025财年净亏损扩大44%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

1

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":455506604474664,"tweetId":"455506604474664","gmtCreate":1752244796023,"gmtModify":1752247544075,"author":{"id":3562560508203735,"idStr":"3562560508203735","authorId":3562560508203735,"authorIdStr":"3562560508203735","name":"Hello不Kitty","avatar":"https://static.tigerbbs.com/a89ace00d7c99ac8f39dea94b04dbbe8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>fda都已经批了，日本，和加拿大市场都打开了&nbsp; 看好</p></body></html>","htmlText":"<html><head></head><body><p>fda都已经批了，日本，和加拿大市场都打开了&nbsp; 看好</p></body></html>","text":"fda都已经批了，日本，和加拿大市场都打开了 看好","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/455506604474664","repostId":1100750260,"repostType":4,"repost":{"id":"1100750260","kind":"news","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"异动解读","id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1752240743,"share":"https://www.laohu8.com/m/news/1100750260?lang=&edition=full","pubTime":"2025-07-11 21:32","market":"sg","language":"zh","title":"异动解读 | Kalvista Pharmaceuticals股价盘中大跌5.53%，2025财年净亏损扩大44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100750260","media":"异动解读","summary":"7月11日周五，Kalvista Pharmaceuticals Inc股价在盘中大跌5.53%，引起市场关注。这一显著跌幅与公司最新发布的2025财年财报密切相关。根据Kalvista Pharmaceuticals公布的财报，公司2025财年净亏损达1.83亿美元，同比扩大44.09%。从资产负债状况来看，Kalvista Pharmaceuticals的财务状况同样不容乐观。公司总负债为1.55亿美元，资产负债比高达1.62，而流动比率仅为0.06，表明公司面临较大的财务压力和流动性风险。作为一家专注于开发小分子蛋白酶抑制剂的制药公司，Kalvista Pharmaceuticals的未来发展仍值得市场持续关注。","content":"<p>7月11日周五，Kalvista Pharmaceuticals Inc（股票代码：KALV）股价在盘中大跌5.53%，引起市场关注。这一显著跌幅与公司最新发布的2025财年财报密切相关。</p>\n\n<p>根据Kalvista Pharmaceuticals公布的财报，公司2025财年净亏损达1.83亿美元，同比扩大44.09%。更值得注意的是，公司报告期内营业收入为0美元，每股基本亏损3.69美元。这些数据显示公司面临严峻的财务挑战，可能是导致投资者信心下降的主要原因。</p>\n\n<p>从资产负债状况来看，Kalvista Pharmaceuticals的财务状况同样不容乐观。公司总负债为1.55亿美元，资产负债比高达1.62，而流动比率仅为0.06，表明公司面临较大的财务压力和流动性风险。尽管如此，分析机构对公司前景仍保持谨慎乐观，9家机构给出的平均目标价为30.89美元，最高目标价达40美元。作为一家专注于开发小分子蛋白酶抑制剂的制药公司，Kalvista Pharmaceuticals的未来发展仍值得市场持续关注。</p>","source":"ai_movement_cn","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | Kalvista Pharmaceuticals股价盘中大跌5.53%，2025财年净亏损扩大44%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | Kalvista Pharmaceuticals股价盘中大跌5.53%，2025财年净亏损扩大44%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-07-11 21:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>7月11日周五，Kalvista Pharmaceuticals Inc（股票代码：KALV）股价在盘中大跌5.53%，引起市场关注。这一显著跌幅与公司最新发布的2025财年财报密切相关。</p>\n\n<p>根据Kalvista Pharmaceuticals公布的财报，公司2025财年净亏损达1.83亿美元，同比扩大44.09%。更值得注意的是，公司报告期内营业收入为0美元，每股基本亏损3.69美元。这些数据显示公司面临严峻的财务挑战，可能是导致投资者信心下降的主要原因。</p>\n\n<p>从资产负债状况来看，Kalvista Pharmaceuticals的财务状况同样不容乐观。公司总负债为1.55亿美元，资产负债比高达1.62，而流动比率仅为0.06，表明公司面临较大的财务压力和流动性风险。尽管如此，分析机构对公司前景仍保持谨慎乐观，9家机构给出的平均目标价为30.89美元，最高目标价达40美元。作为一家专注于开发小分子蛋白酶抑制剂的制药公司，Kalvista Pharmaceuticals的未来发展仍值得市场持续关注。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100750260","content_text":"7月11日周五，Kalvista Pharmaceuticals Inc（股票代码：KALV）股价在盘中大跌5.53%，引起市场关注。这一显著跌幅与公司最新发布的2025财年财报密切相关。\n根据Kalvista Pharmaceuticals公布的财报，公司2025财年净亏损达1.83亿美元，同比扩大44.09%。更值得注意的是，公司报告期内营业收入为0美元，每股基本亏损3.69美元。这些数据显示公司面临严峻的财务挑战，可能是导致投资者信心下降的主要原因。\n从资产负债状况来看，Kalvista Pharmaceuticals的财务状况同样不容乐观。公司总负债为1.55亿美元，资产负债比高达1.62，而流动比率仅为0.06，表明公司面临较大的财务压力和流动性风险。尽管如此，分析机构对公司前景仍保持谨慎乐观，9家机构给出的平均目标价为30.89美元，最高目标价达40美元。作为一家专注于开发小分子蛋白酶抑制剂的制药公司，Kalvista Pharmaceuticals的未来发展仍值得市场持续关注。","news_type":1,"symbols_score_info":{"KALV":1}},"isVote":1,"tweetType":1,"viewCount":549,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":43,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/455506604474664"}